TNF Pharmaceuticals Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 0/6
TNF Pharmaceuticals has been growing earnings at an average annual rate of 3.7%, while the Pharmaceuticals industry saw earnings declining at 0.2% annually.
Anahtar bilgiler
3.7%
Kazanç büyüme oranı
15.5%
EPS büyüme oranı
| Pharmaceuticals Sektör Büyümesi | 6.0% |
| Gelir büyüme oranı | n/a |
| Özkaynak getirisi | -4,626.4% |
| Net Marj | n/a |
| Son Kazanç Güncellemesi | 30 Jun 2024 |
Yakın geçmiş performans güncellemeleri
Güncelleme yok
Recent updates
We Think MyMD Pharmaceuticals (NASDAQ:MYMD) Needs To Drive Business Growth Carefully
Sep 01
We're Keeping An Eye On MyMD Pharmaceuticals' (NASDAQ:MYMD) Cash Burn Rate
May 19MyMD Pharma receives grant from European patent office for Supera-CBD compound
Aug 30Oramed, MyMD surge on plans for early-stage oral COVID vaccine data release in Q3
Jul 08Companies Like MyMD Pharmaceuticals (NASDAQ:MYMD) Could Be Quite Risky
Apr 12MyMD Pharmaceuticals (NASDAQ:MYMD) Is In A Good Position To Deliver On Growth Plans
Aug 29Gelir ve Gider Dağılımı
TNF Pharmaceuticals nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
| Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -23 | 7 | 6 |
| 31 Mar 24 | 0 | -18 | 9 | 8 |
| 31 Dec 23 | 0 | -8 | 8 | 8 |
| 30 Sep 23 | 0 | -7 | 8 | 7 |
| 30 Jun 23 | 0 | -14 | 8 | 7 |
| 31 Mar 23 | 0 | -13 | 6 | 7 |
| 31 Dec 22 | 0 | -15 | 6 | 9 |
| 30 Sep 22 | 0 | -15 | 7 | 7 |
| 30 Jun 22 | 0 | -16 | 7 | 9 |
| 31 Mar 22 | 0 | -31 | 22 | 8 |
| 31 Dec 21 | 0 | -30 | 21 | 7 |
| 30 Sep 21 | 0 | -31 | 22 | 7 |
| 30 Jun 21 | 0 | -29 | 22 | 5 |
| 31 Mar 21 | 0 | -12 | 6 | 4 |
| 31 Dec 20 | 0 | -9 | 6 | 2 |
| 31 Dec 19 | 0 | -10 | 6 | 4 |
Kaliteli Kazançlar: TNFA is currently unprofitable.
Büyüyen Kar Marjı: TNFA is currently unprofitable.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: TNFA is unprofitable, but has reduced losses over the past 5 years at a rate of 3.7% per year.
Büyüme Hızlandırma: Unable to compare TNFA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Kazançlar vs. Sektör: TNFA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.4%).
Özkaynak Getirisi
Yüksek ROE: TNFA has a negative Return on Equity (-4626.36%), as it is currently unprofitable.